NZ299257A - Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase - Google Patents
Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNaseInfo
- Publication number
- NZ299257A NZ299257A NZ29925796A NZ29925796A NZ299257A NZ 299257 A NZ299257 A NZ 299257A NZ 29925796 A NZ29925796 A NZ 29925796A NZ 29925796 A NZ29925796 A NZ 29925796A NZ 299257 A NZ299257 A NZ 299257A
- Authority
- NZ
- New Zealand
- Prior art keywords
- accumulation
- patients
- pulmonary disease
- purulent material
- treating purulent
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The use of deaminated human Dnase in the manufacture of a medicament for the treatment of accumulated purulent material and pulmonary diseases.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8953392A | 1992-06-08 | 1992-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ299257A true NZ299257A (en) | 2000-08-25 |
Family
ID=22218180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ29925796A NZ299257A (en) | 1992-06-08 | 1996-08-29 | Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase |
Country Status (1)
Country | Link |
---|---|
NZ (1) | NZ299257A (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
US8710012B2 (en) | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
US8871200B2 (en) | 2006-11-28 | 2014-10-28 | Cls Therapeutics Limited | Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method |
US8916151B2 (en) | 2005-04-25 | 2014-12-23 | Cls Therapeutics Limited | Method for treating a reduction of fertility |
US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
US11701410B2 (en) | 2015-05-22 | 2023-07-18 | Cls Therapeutics Limited | Extracellular DNA as a therapeutic target in neurodegeneration |
US11905522B2 (en) | 2018-01-16 | 2024-02-20 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
-
1996
- 1996-08-29 NZ NZ29925796A patent/NZ299257A/en not_active IP Right Cessation
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9463223B2 (en) | 2003-07-14 | 2016-10-11 | Cls Therapeutics Limited | Method for monitoring development of somatic mosaicism |
US9248166B2 (en) | 2003-07-14 | 2016-02-02 | Cls Therapeutics Limited | Method for treating oncological diseases |
US8535663B2 (en) | 2003-07-14 | 2013-09-17 | Cls Therapeutics Limited | Method for treating delayed-type hypersensitivity |
US8710012B2 (en) | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
US8796004B2 (en) | 2003-07-14 | 2014-08-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
US9845461B2 (en) | 2003-07-14 | 2017-12-19 | Cls Therapeutics Limited | Method for treating oncological diseases |
US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
US9072733B2 (en) | 2003-07-14 | 2015-07-07 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
US9770492B2 (en) | 2003-07-14 | 2017-09-26 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
US8916151B2 (en) | 2005-04-25 | 2014-12-23 | Cls Therapeutics Limited | Method for treating a reduction of fertility |
US8871200B2 (en) | 2006-11-28 | 2014-10-28 | Cls Therapeutics Limited | Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method |
US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
US11701410B2 (en) | 2015-05-22 | 2023-07-18 | Cls Therapeutics Limited | Extracellular DNA as a therapeutic target in neurodegeneration |
US11905522B2 (en) | 2018-01-16 | 2024-02-20 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU9301978D0 (en) | Application of complementary inhibitors in medical preparatives used for treatment of inflammatory diseases of intestines and skin | |
HU9602583D0 (en) | Gel for treatment of skin diseases and for disinfection of the skin | |
CA2116559A1 (en) | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases | |
NZ501069A (en) | Monoesters of probucol for the treatment of cardiovascular and inflammatory disease | |
DE69721766D1 (en) | NEW MEDICAL FORMULATION | |
PT668763E (en) | USE OF FENSERIN FOR THE PREPARATION OF MEDICINES TO TREAT DISEASES OF KNOWLEDGE | |
AU1197992A (en) | The use of loperamide and related compounds for treatment of respiratory disease symptoms | |
NO933000D0 (en) | USE OF C1 INACTIVATOR FOR THE PREPARATION OF A MEDICINE FOR PROPHYLAXY AND TREATMENT OF CERTAIN DISEASES | |
NZ299257A (en) | Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase | |
IL112288A (en) | Use of riluzole in the manufacture of a medicament for the treatment of mitochondrial diseases | |
EP0744176A3 (en) | Methods for inhibiting bone loss | |
AU3733295A (en) | Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i | |
EP0795332A3 (en) | Medical use of gamma-interferon in interstitial lung diseases | |
AU1898792A (en) | Treatment or therapeutic booth for energetic, cosmetic and medical purposes | |
NZ307601A (en) | Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions | |
AU2143892A (en) | Use of formoterol for treatment of tissue injury | |
ZA933567B (en) | Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatment of Alzheimer's disease | |
NO307126B1 (en) | Use of biologically active ureido derivatives for the manufacture of a medicament for use in the treatment of lentivirus-induced disease | |
NZ268039A (en) | Use of efaroxan in treating parkinson's disease | |
WO2001019359A3 (en) | Medicaments containing pantothenic acid for the treatment of inflammatory joint disease | |
MY112888A (en) | Use of bradykinin antagonists for the preparation of medicaments for the treatment of virus diseases. | |
EP0673646A3 (en) | Use of Deoxypergualin in the manufacture of a medicament for the treatment of inflammatory-hyperresponsiveness diseases. | |
AU8195091A (en) | Ropinirole and domperidone for use in the manufacture of a medicament for the treatment of parkinson's disease | |
LV5179A3 (en) | Preparation of "ethoxidine" for prophylaxis and treatment of almost all diseases of the lungs and bowels | |
WO1998024421A3 (en) | Use of dextrin sulphate for the treatment of highly vascular tumours |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
EXPY | Patent expired |